Vaxart Inc., of South San Francisco, reported results from a phase II trial testing its H1 influenza oral tablet vaccine compared to an injectable quadrivalent influenza vaccine (QIV). In the challenge study, Vaxart's influenza oral tablet vaccine provided a 39 percent reduction in clinical disease relative to placebo, compared to a 27 percent reduction by QIV.